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Inducible expression of human immunodeficiency virus (HIV) is regulated by a cellular transcription factor,
nuclear factor KB (NF-*cB). NF-KB is composed of distinct subunits; five independent genes, NFKBl(plO5),
NFKB2(plOO), ReIA(p65), c-rel and reiB, that encode related proteins that bind to KB DNA elements have been
isolated. We have previously found that NFKB2(p49/p52) acts in concert with RelA(p65) to stimulate the HIV
enhancer in Jurkat T-leukemia cells. Here we examine the biochemical basis for the transcriptional regulation
of HIV by NFKB2. Using Scatchard analysis, we have determined the dissociation constants of homodimeric
p49 and heterodimeric p49/p65 for binding to the HIV KB site. p49 has a -18-fold-lower affinity for the HIV
KB site (KD = 69.1 pM) than does the -50-kDa protein NFKB1(p5O) derived from p105 (KD = 3.9 pM). In
contrast, the affinity of heterodimeric NFKB2(p49)/ReIA(p65) for this site is --6-fold higher (KD = 11.8 pM)
than that of p49 alone. Consistent with these findings, in vitro transcription was stimulated 18-fold by the
addition of preformed, heterodimeric NFKB2(p49)/ReIA(p65) protein. Transcriptional activation of the HIV
enhancer was also subject to regulation by recently cloned IKB-ae(MAD-3). Recombinant IKB-ct(MAD-3)
inhibited the DNA binding activity of p65, p49/p65, and p5O/p65 but stimulated the binding of NFKB2(p49) or
NFKBl(p5O). Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat
T-leukemia cells was also inhibited by coexpression of MAD-3. These data suggest that binding of the NFKB2
subunit to the HIV enhancer is facilitated by RelA(p65) and that this NFKB2(p49)/p65 heterodimeric complex
mediates transcriptional activation which is subject to regulation by MAD-3.
Nuclear factor KB (NF-KB) is a family of sequence-specific
DNA-binding proteins which regulate the transcription of a
variety of cellular and viral genes (1, 26). These transcription
factors can be detected in the cytoplasm of many cells (3) in
association with IKB's, factors which inhibit their DNA-
binding activity (2, 47). The DNA-binding activity of NF-KB
can be stimulated by cellular activation with cytokines (37)
or viral trans-activators (6, 28, 39). Cellular protein kinases
can alter the phosphorylation of IKB's (13, 29), leading them
to dissociate from NF-KB. This dissociation is likely to serve
as an important regulatory step which makes NF-KB avail-
able for binding to KB elements in the promoters of genes
involved in immune and inflammatory responses (26, 27). In
addition to these cellular genes, NF-KB can also activate the
transcription of genes encoded by eukaryotic viruses.
Among these, the human immunodeficiency virus (HIV)
enhancer contains two KB sites which play an important role
in inducible activation of viral transcription (33).
Biochemical and molecular biological analysis of NF-KB
has begun to reveal the complexity of this transcriptional
regulatory pathway. Highly purified NF-KB is composed of
two major subunits, with molecular masses of -50 and -65
kDa, respectively (4, 20). Isolation of cDNAs encoding the
50-kDa subunit (p5O) suggested that the primary translation
product of this subunit is a -105-kDa protein which requires
posttranslational modification to obtain the mature form (8,
14, 22, 32). Sequence comparison of p5O and the gene
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encoding the 65-kDa subunit (p65) (36, 40) revealed a high
homology to the c-rel proto-oncogene (9) and to the Dros-
ophila morphogen dorsal (44). We have recently described
another gene, p49/plOO, which can generate an alternative
-50-kDa form of NF-KB (7, 34, 43). A -50-kDa protein can
be generated either by posttranslational processing of a
-100-kDa precursor or by the generation of an alternatively
spliced form, p49; the N termini of p49 and plO are
identical, and p49 appears to be functionally indistinguish-
able from truncated forms of plO (38). The gene encoding
this product has been designated NFKB2, in contrast to the
p105 subunit, which has been termed NFKB1 (30a).
A human cDNA clone that encodes a 35- to 37-kDa protein
has been isolated. The protein, MAD-3, has been shown to
have IKB-like properties (16). Purification and primary se-
quence analysis of rabbit IKB (10) has revealed its identity to
MAD-3. The MAD-3/IKB protein contains five repeats of a
sequence that was first identified in the erythroid protein
ankyrin and is also present in a number of proteins involved
in cell cycle control and tissue differentiation (35). The C
termini of p1O0 and p105 also contain ankyrin/cell cycle
repeats, and the C terminus of p105 has been shown to have
IKB-like activity when expressed in trans (17, 30).
Cotransfection studies with p5O NFKB1 and p49 NFKB2
expression vectors have shown that these two genes, despite
their homology, differ in the ability to activate KB-dependent
transcription of the HIV enhancer in combination with
RelA(p65) (38, 43). Here we characterize the biochemical
properties of recombinant p49 as well as its interactions with
p65 and with MAD-3 (16). The binding constants of p49
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homodimers and p49/p65 heterodimers to both the HIV KB
site and the related H-2 site (5, 18) are determined, and the
ability of NFKB2(p49)/RelA(p65) proteins to stimulate in
vitro transcription of the HIV enhancer is characterized. We
show that heterodimeric NFKB2(p49)/RelA(p65) has a
higher affinity for KB than does NFKB2(p49), stimulates
transcription of HIV in vitro and in vivo, and is subject to
regulation by IKB-a/MAD-3 mediated through the RelA(p65)
subunit.
MATERLILS AND METHODS
Plasmids. Human p5O NFKB2, a -50-kDa N-terminal
truncated form of p105, was generated from Rous sarcoma
virus (RSV)-p105 by using site-directed mutagenesis to cre-
ate a stop codon at the position corresponding to residue
453, followed by a BglII restriction site. Utilization of the
previously created HindIII and NcoI sites 5' of the Kozak
sequence (23) of RSV-plO5 (38) allowed subcloning into the
RSV and pET3D vectors as previously described (43).
Human p65 was isolated from a B-cell lymphoma cDNA
library probed with a polymerase chain reaction-derived
mouse p65 cDNA clone. The human clone appears to be
identical to that described previously (40, 41). 3' untrans-
lated sequence was removed by digestion with BsaHI, and
the 5' overhang was filled in with Klenow enzyme. The NcoI
site at the initiation ATG was used to subclone into the
modified RSV ,-globin vector (43), thus inserting a consen-
sus Kozak sequence.
The MAD-3 cDNA (16) was kindly provided by Chiron
Inc. and subcloned into the modified RSV vector (43) by
ligation of an XbaI-Klenow-HindIII MAD-3 fragment into
the modified RSV 0-globin-derived backbone (43).
The HIV long terminal repeat (LTR) in vitro transcription
template (pHIV380) was prepared by blunt-end ligation of a
-730-bp XhoI-HindIII Klenow-treated fragment from an
HIV-chloramphenicol acetyltransferase (CAT) construct
into the SacI site of the p(C2AT)19 G-less cassette vector
(42), whose 3' overhangs had been removed by treatment
with T4 polymerase. The adenovirus major late plasmid,
pML200 (31), was a kind gift of U. Schibler, University of
Geneva.
All other expression vectors and KB reporter plasmids
have been described previously (33, 38).
Protein purification and formation of heterodimers. p49 and
p5O proteins were expressed in Escherichia coli BL21(LysE)
and partially purified by Sephacryl S-200 gel filtration fast
protein liquid chromatography as described previously (38).
Proteins were affinity purified by oligonucleotide chromatog-
raphy (19), using the H-2 site as the target sequence (46).
Proteins were eluted with a linear NaCl gradient in a buffer
containing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid (HEPES; pH 7.9), 1 mM EDTA, 0.1 mM
ZnCl2, 0.1% Nonidet P-40, 10% glycerol, 0.1 mM phenyl-
methylsulfonyl fluoride, and 0.5 mM dithiothreitol, dialyzed
against the same buffer with 50 mM NaCl, and stored in
aliquots at -70°C. Proteins were judged to be at least 90%
pure by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) analysis. Heterodimers were
formed by incubating concentrated proteins in a 3-,ul volume
for 15 to 40 min at 37°C and then diluting the mixture in the
same dialysis buffer containing 0.1 mg of bovine serum
albumin per ml.
Recombinant murine p65 protein, expressed in baculovi-
rus (11), was a kind gift of T. Fujita, G. Nolan, and D.
Baltimore.
Expression and purification of MAD-3 protein as a fusion
protein with glutathione S-transferase (GST) will be de-
scribed elsewhere (22a).
EMSA and chemical cross-linking. Proteins were incubated
with radiolabeled DNA probes in a 20-p.l reaction mixture
containing 10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM
dithiothreitol, 0.1 mg of bovine serum albumin per ml, 3%
glycerol, 50 ,uM MgCl2, and 10 ,uM ATP. Nucleoprotein
complexes were resolved by electrophoresis on 4% nonde-
naturing polyacrylamide gels in 0.25 x Tris-borate-EDTA at
10 V/cm for 5 h at room temperature. Dried gels were
exposed to Kodak XAR-5 film at -70°C with intensifying
screens. The DNA probes used in this study were (i) a
182-bp ScaI-NheI restriction fragment from an HIV-1 LTR
plasmid in which site-directed mutagenesis had been used to
abolish the 3' KB site to eliminate the possibility of cooper-
ative binding and double occupancy (Fig. 1A), (ii) a double-




and (iii), a double-stranded oligonucleotide probe encoding a




The KB motifs are shown in bold. Oligonucleotides were
radiolabeled by using Klenow enzyme and [32P]dCTP; -0.5
ng was used in a standard electrophoretic mobility shift
assay (EMSA) reaction.
For cross-linking, purified homodimeric and heterodi-
meric proteins (200 to 1,600 ng) were incubated with 4-ethyl-
eneglycol bis(sulfosuccinimidyl succinate) (EGS; Pierce) for
15 min at room temperature in a 40-,ul volume in the dilution
buffer described above. The reaction was stopped by the
addition of D-lysine (25 mM, final concentration), and one
half of each sample was resolved by electrophoresis on a
SDS-6% polyacrylamide gel and immunoblotting with an
anti-plOO polyclonal antibody (38a) followed by a goat
anti-rabbit horseradish peroxidase conjugate; the reaction
was developed by using the ECL Western immunoblotting
detection system (Amersham).
Determination of dissociation constants. Dissociation con-
stants were determined essentially as described previously
(11, 48). Gel-purified oligonucleotides encoding either the








The KB elements are shown in bold. Annealed oligonucle-
otides were radiolabeled with [a-32P]dATP by using Klenow
enzyme and chased with unlabeled dATP and dGTP. Unin-
corporated radionucleotides were removed by Sephadex
G-50 gel filtration. Probes used were of a specific activity of
at least 50,000 Ci/mmol. The concentration of active DNA-
binding sites was calculated by EMSA analysis using a large
excess of probe, and a constant amount of protein (-1 fmol)
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FIG. 1. Formation of NFKB2(p49) multimers in vitro. (A) NFKB2(p49), NFKB1(p50), and ReIA(p65) proteins were incubated as
NFKB2(p49) alone (lane 1), heterodimeric NFKB2(p49)/ReIA(p65) (0.25 ng/2 ng; lane 2), NFKB1(p50) alone (0.12 ng; lane 3), heterodimeric
NFKB1(pSO)/ReLA(p65) (0.12 ng/0.8 ng; lane 4), or an excess of Re1A(p65) (4 ng) to compare its binding activity (lane 5) as described in
Materials and Methods. A radiolabeled restriction fragment derived from the HIV-1 LTR was used under standard conditions, except that
reaction mixtures contained 100 ng of poly(dI-dC) poly(dI-dC). Nucleoprotein complexes were resolved by EMSA. (B) Formation of
higher-order complexes at high protein concentration. Serial dilutions of NFKB2(p49) (50, 5, and 0.5 ng; lanes 6 to 8) and NFKB1(p50) (25,
2.5, and 0.25 ng; lanes 9 to 11) were incubated with a radiolabeled HIV cB probe and analyzed by EMSA under standard conditions. (C)
Chemical cross-linking of NFKB2(p49) and ReIA(p65). NFKB2(p49) and ReJA(p65) proteins were incubated with EGS and analyzed by
SDS-PAGE and immunoblotting with a polyclonal antibody specific to p49/plOO as described in Materials and Methods. Positions of native
(arrow 1) and cross-linked (arrows 2, 3, and 4) species are indicated.
was incubated with a range of probe concentrations in a
10-jtl reaction for 10 min under standard EMSA conditions
for 1 h at room temperature. Dried gels were analyzed by
using a Betascope analyzer (Betagen).
In vitro transcription. In vitro transcription experiments
were performed with nuclear extracts from HeLa cells
(HeLaScribe; Promega). Extracts (50 pg) were incubated at
30'C for 30 min in a 25-ptl reaction volume containing ATP
and CTP (all at 0.4 mM), 1 pul of [a-32P]UTP (3,000 Ci/mmol;
Amersham), 7.5 mM MgCl2, 100 ng each of plasmids
pHIV380 and pML200, 10 mM HEPES (pH 7.9), 50 mM
KCl, 0.1 mM EDTA, 0.2mM dithiothreitol, and 8% glycerol.
RNase T1 (150 U; Bio-Rad) was added, and samples were
incubated for a further 15 min. RNA was recovered by
phenol-chloroform extraction followed by ethanol precipita-
tion and resolved on 6% sequencing gels. Dried gels were
exposed to Kodak XAR-5 film at -70'C with intensifying
screens, and autoradiograms were analyzed by digital scan-
ning, using hardware and software from BioImage Inc. (Ann
Arbor, Mich.).
Transfections and CAT assays. Cell culture, transfections,
and CAT assays were performed as described previously
(43).
RESULTS
Dimerization and DNA binding of NFKB2(p49). The DNA-
binding properties of recombinant NFKB2(p49) and
NFKB1(p50) were compared by using the EMSA. When
purified, recombinant p49 protein was combined with recom-
binant RelA(p65) and incubated with an HIV KB site probe,
a novel complex with a mobility distinct from that of either
subunit alone was detected (Fig. 1A, lane 2 versus 1 and 5).
A similar complex was also observed with NFKB1(p50) in
combination with ReIA(p65) (Fig. 1A, lane 4), consistent
with previous findings that both NFKB2(p49) and
NFKB1(p50) can form heterodimeric complexes with Re-
lA(p65) (7, 36, 38). At high protein concentrations of p49
(Fig. 1B, lanes 6 to 8) and p50 (Fig. 1B, lanes 9 to 11),
complexes with lower mobility were observed, suggesting
that NFKB2(p49) and NFKB1(p50) are able to form higher-
order oligomers. To investigate this observation further, the
p49-containing complexes were incubated with the bifunc-
tional chemical cross-linking agent EGS, resolved by SDS-
PAGE, and detected by immunoblotting with an antiserum
specific to p49. While native NFKB2(p49) migrated as pre-
dicted by its molecular weight (Fig. 1C, lane 12, arrow 1),
cross-linked protein migrated predominantly as a -100-kDa
species, while a minor -200-kDa band was also present (Fig.
1C, lane 13, arrows 2 and 4). These data suggest that NFKB2
exists predominantly in a dimeric form in solution. Cross-
linked heterodimeric NFKB2/RelA migrated at a position
consistent. with the predicted size of the heterodimer (Fig.
1C, lane 14, arrow 3).
To examine the DNA-binding properties of NFKB2, the
dissociation constants of binding to different KB sites were
determined. Oligonucleotides were radiolabeled to high spe-
cific activity, and dilutions of probe were incubated with a
constant concentration of protein. Bound and free DNA
species were resolved by gel electrophoresis, and dissocia-
tion constants were determined by Scatchard analysis. The
affinity of homodimeric NFKB2(p49) for the HIV KB site
was approximately 18 times weaker than that of
NFKB1(p50) (Fig. 2). Also, homodimeric p49 showed a
higher affinity for the H-2 KB element than for the HIV KB
site (Fig. 3), consistent with previous studies in which this
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FIG. 2. Affinity of NFKB2(p49) and NFKB1(p50) for the HIV
KB site. To determine dissociation constants of homodimeric
NFKB2(p49) and NFKB1(p50) for binding to the HIV KB (GGG
GACTTTCC) site, a constant amount of purified subunit (-1 fmol
active protein) was incubated with a range of radiolabeled probe
concentrations, in a 10-,ul reaction, and analyzed by EMSA as
described in Materials and Methods. Bound (B) and free (F) probe
species were quantitated by using a Betascope analyzer (Betagen),
and dissociation constants were determined by Scatchard analysis.
Reactions were performed in triplicate.
difference had not been quantitated (7, 34, 38). However,
heterodimeric NFKB2(p49)/RelA(p65) showed a five- to
sixfold-higher affinity for the HIV site than did p49 alone
(Fig. 3A). The association of NFKB2(p49) with RelA(p65)
increased its affinity for the palindromic H-2 KB site less than
twofold under the same conditions (Fig. 3B).
NFKB2(p49)/RelA(p65) heterodimers stimulate HIV tran-
scription in vitro. The effect of heterodimeric NFKB2(p49)/
RelA(p65) protein on the transcriptional control of HIV was
examined in vitro by using a reporter plasmid in which the
HIV LTR was cloned upstream of the synthetic (C2AT)19
cassette (42) to allow the transcription of a -380-nucleotide
RNA transcript lacking guanosine residues. LTR-directed








FIG. 4. Analysis of HIV transcription by heterodimeric
NFKB2(p49) and RelA(p65) in vitro. Nuclear extracts from HeLa
cells were incubated with 100 ng each of plasmids pHIV380 and
pML200, in the presence of RNase T1 and [a-32P]UTP as described
in Materials and Methods, along with 100 ng of recombinant
NFKB2(p49) and RelA(p65) proteins as indicated. RNA transcripts
were recovered and analyzed on 6% sequencing gels. AdML,
adenovirus major late promoter.
cells programmed with the HIV plasmid in the presence of
RNase T1, which rapidly degrades all G-containing tran-
scripts. Addition of preformed, heterodimeric NFKB2(p49)/
RelA(p65) stimulated transcription of HIV up to 18-fold (Fig.
4, lane 4), while addition of a similar quantity of
NFKB2(p49) or RelA(p65) alone stimulated HIV transcrip-
tion only 1.4-fold (lane 2) or 6.8-fold (lane 3), respectively, as
determined by digital scanning analysis of the autoradiogram
shown in Fig. 4. Transcription of a -200-bp cassette driven
by the KB-independent adenovirus major late promoter was
not significantly affected by the addition of NFKB2(p49) and
RelA(p65) proteins.
Binding of heterodimeric NFKB2(p49)/RelA(p65) to DNA is
blocked by MAD-3 protein. The effect of the MAD-3 gene
product on the DNA binding of NFKB2(p49) was next
examined. Recombinant MAD-3 protein, expressed in E.
coli and purified as a fusion protein with GST, was incubated
with combinations of NF-KB subunits and analyzed by
EMSA. Addition of GST-MAD-3 protein inhibited the DNA
binding of RelA(p65) alone (Fig. 5, lanes 1 and 2). Recom-
binant MAD-3 protein had no inhibitory effect on
NFKB2(p49) or NFKB1(p50) binding alone and in fact
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FIG. 3. Comparison of affinities of NFKB2(p49) and heterodimeric NFKB2(p49)/RelA(p65) for the HIV or class I major histocompatibility
complex KB sites by Scatchard analysis of binding to the HIV (GGGGACYTTCC) (A) and H-2 KB (GGGGAATCCCC) (B) sites.
NFKB2(p49)/RelA(p65) heterodimers were formed as described in Materials and Methods, and dissociation constants were determined as
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FIG. 5. Effects of recombinant MAD-3 on DNA binding of
NF-KB proteins. MAD-3 protein expressed as a fusion protein with
GST (100 ng) or a GST control was incubated under standard
EMSA conditions with recombinant RelA(p65) (lanes 1 and 2),
NFKB2(p49) (lanes 3 and 4), heterodimeric NFKB2(p49)/RelA(p65)
(lanes 5 and 6), p50 (lanes 7 and 8), heterodimeric NFKBl(p5O)/
RelA(p65) (lanes 9 and 10), recombinant Spl (lanes 11 and 12), or
alone (lanes 13 and 14). EMSA was performed as described in
Materials and Methods.
(Fig. 5, lanes 3 versus 4 and 7 versus 8). When GST-MAD-3,
in contrast to GST, was incubated with either NFKB2(p49)/
RelA(p65) or NFKB1(p49)/RelA(p65) heterodimers, both
DNA-binding activities were strongly inhibited (Fig. 5, lanes
5 versus 6 and 9 versus 10), suggesting that neither NFKB1
nor NFKB2 affected the ability of MAD-3 to interact with its
target sequence on RelA(p65). Addition of MAD-3 to p49/
p65 or p5O/p65 heterodimers, while inhibiting the binding of
the heterodimeric complex, also stimulated the appearance
of nucleoprotein complexes identical in mobility to the
respective homodimer, again suggesting that MAD-3 can
interact directly with NFKB2(p49) and NFKB1(p5O) to
enhance their DNA-binding properties. MAD-3 had no effect
on the binding of recombinant Spl protein to its cognate site
(Fig. 5, lanes 11 and 12), confirming that these inhibitory and
stimulatory effects were specific.
Transcriptional activation of the HIV enhancer by
NFKB2(p49)/ReIA(p65) in transfected Jurkat cells is inhibited
by MAD-3. To determine whether transcriptional activation
by p49/p65 heterodimers could be inhibited by MAD-3 in a T
cell, expression vectors encoding different NF-KB subunits
and MAD-3 were cotransfected into Jurkat T-lymphoma
cells together with reporter plasmids containing the HIV
enhancer linked to the CAT gene. Cotransfection of equal
amounts of p49 and p65 plasmids stimulated transcription
mediated through the HIV LTR approximately 13-fold.
Consistent with previous reports, this transactivation was
more potent with NFKB2(p49)/RelA(p65) than with
NFKB1(p50)/ReLA(p65) expression vectors (38, 43). Co-
transfection of an expression plasmid encoding MAD-3
almost completely inhibited the stimulation observed with
both p49/p65 and p50/p65 (Fig. 6A). This effect was also seen
with a reporter plasmid bearing the heterologous simian
virus 40 promoter containing multiple KB sites (data not
shown). MAD-3 had no inhibitory effect on the KB-indepen-
dent transcription stimulation of HIV by the cytomegalovi-
rus immediate-early gene product and did not significantly
inhibit CAT transcription mediated by the RSV LTR (Fig.
6B). In addition, this effect was observed in a dose-respon-
sive manner (Fig. 6C). These data demonstrate that MAD-3
exerts its inhibitory effect specifically through NF-KB, most
likely through its interaction with RelA(p65).
DISCUSSION
We have examined the biochemical basis for NFKB2
binding to KB and its ability to dimerize and interact func-
tionally with p65 and MAD-3. We find that the affinities
and specificities of DNA binding by NFKB2(p49) and
NFKB1(p50) differ considerably. Notably, binding of
NFKB2(p49)/RelA(p65) to KB shows more than fivefold-
greater affinity than does binding of NFKB2(p49), and this
heterodimer stimulates transcription of the HIV enhancer
in vitro. The interaction of heterodimers of NF-KB,
NFKB2(p49)/RelA(p65) and NFKB1(p50)/RelA(p65), was
inhibited by the MAD-3 IKB, but neither NFKB2(p49) nor
NFKB1(p50) binding was inhibited by MAD-3. The finding
that NFKB2(p49)/RelA(p65) stimulates transcription of the
HIV enhancer in vitro (Fig. 4) documents that NFKB2(p49)
and ReLA(p65) act in concert to stimulate HIV transcription.
Previous studies had shown that overexpression of
NFKB2(p49). and RelA(p65) stimulated KB-dependent re-
porter gene transcription in transfected cells, but the possi-
bility remained that this effect was indirect, (e.g., due to
the initiation of a cascade of stimulatory events or an
association with endogenous cellular factors). The data
reported here suggest that NFKB2(p49)/RelA(p65) exerts a
direct stimulatory effect on transcriptional initiation. Recent
studies have suggested that homodimeric NFKB1(p50) pro-
tein may stimulate KB-dependent transcription indepen-
dently of ReIA(p65) (11, 24); the in vitro transcription data
presented here suggest that this is not the case for
NFKB2(p49), since transcription of the HIV enhancer was
not significantly stimulated by NFKB2(p49) alone (Fig. 4,
lanes 1 and 2).
The weak affinity of homodimeric NFKB2(p49) for KB
motifs (Fig. 2 and 3) relative to NFKBl(p5O), as well as its
site specificity, highlight significant differences between
NFKB2(p49) and NFKB1(p5O). The affinity of recombinant
NFKB2(p49) for the HIV KB site (KD = 69.1 pM) is 17.7
times lower than that of NFKB1(p5O) (KD = 3.9 pM) under
the same conditions. The bindingKD of NFKB1(p5O) for the
HIV KB site compares very favorably with results of a
previous report (11; 3.9 pM versus 6.7 pM) which used
nearly identical experimental conditions. While the affinities
of NFKB1(p5O) for the H-2 KB and HIV KB sites are very
similar (10a, 11), NFKB2(p49) has a four- to fivefold-higher
affinity for the H-2 site (KD = 15.7 pM) than for the HIV KB
site (KD = 69.1 pM). Heterodimeric NFKB2(p49)/RelA(p65)
also binds to the HIV KB site with -6-fold-higher affinity
(KD = 11.8 pM) than does NFKB2(p49) alone. This differ-
ence in affinity is not observed with NFKB1(p5O), whose
affinities for the HIV element as either a homodimer or a
NFKB1(p50)/(RelA(p65) heterodimer (6.7 pM versus 5.7 pm
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FIG. 6. Evidence that stimulation of KB-dependent CAT activity by NFKB2(p49) and RelA(p65) expression vectors is blocked by
coexpression of MAD-3 in vivo. (A) Jurkat cells were cotransfected with 5 pug of HIV-CAT reporter plasmid, 0.2 pug of an expression vector
encoding NFKB2(p49), NFKB1(p50), or RelA(p65) as indicated, 0.5 pg of RSV-MAD-3 expression vector as indicated (open bars), or 0.5
,ug of an RSV-p-galactosidase control (filled bars). Transfections and CAT assays were performed as described in the text; CAT activity is
shown as percent conversion. (B) Effect of MAD-3 on KB-independent CAT transcription. A 0.5-Lg sample of MAD-3 or a promoter control
was cotransfected with 2 pg of RSV-CAT (15) or 5 pug of a KB-mutated HIV-CAT reporter plasmid with a plasmid expressing the
cytomegalovirus (CMV) immediate-early gene (12) as indicated. (C) Dose-response inhibition of p49/p65-mediated activation by MAD-3.
NFKB2(p49)/RelA(p65) vectors (0.2 ,ug) with HIV-CAT (5 pg) or RSV-CAT (2 pug) were cotransfected with the indicated amounts of MAD-3
or RSV promoter control and assayed for CAT activity as described in the text. All data are representative of at least four independent
transfections.
affinity of the NFKB2(p49)/RelA(p65) complex for KB may
explain why NFKB2 was not identified initially by primary
amino acid sequence from affinity-purified NF-KdB.
Previous studies have shown that the RelA(p65) subunit
can bind to the 3' (Cl7YfCC) half-site of the HIV cB
sequence, although with low affinity (45). It is therefore
likely that the binding of NFKB2(p49) is stabilized by the
affinity of RelA(p65) for this half-site. Although the affinity of
NFKB2(p49) for KB has been shown to be considerably
weaker than that of NFKBl(p5O), NFKB2(p49) nonetheless
stimulates the KB-directed transcription of several genes
more potently than does NFKB1(p50) when associated with
RelA(p65) (Fig. 6A) (38). Taken together, these findings
suggest that the affinity of binding to DNA is not the only
determinant of the specificity of transcriptional activation for
the HIV enhancer.
Despite their differences in DNA-binding affinity, the
interactions of both NFKB2(p49) and NFKB1(p50) with
RelA(p65) and MAD-3 were indistinguishable. In DNA-
binding experiments, MAD-3 inhibited the binding of any
complex which contained RelA(p65), regardless of its asso-
ciated subunit (Fig. 5). Surprisingly, the binding of ho-
modimeric NFKB2(p49) and NFKB1(p50) was stimulated
by MAD-3. Although MAD-3 inhibited the binding of
heterodimeric NFKB2(p49)/Rel(p65) and NFKB1(pSO)/
RelA(p65) to DNA, in the same reaction it was found to
stimulate the appearance of homodimeric NFKB2(p49) and
NFKB1(p50), respectively. While MAD-3 may conceivably
exert these stimulatory effects by disrupting the het-
erodimeric complex and sequestering RelA(p65), allowing
newly formed homodimeric NFKB2(p49) or NFKB1(p50) to
bind, we believe it more likely that MAD-3 can directly
stimulate the binding of NFKB2(p49) and NFKB1(p50),
since the same effect is observed with homodimeric
NFKB2(p49) and NFKB1(p50). We postulate that our prep-
arations of heterodimeric protein contain a small amount of
homodimeric NFKB2(p49) or NFKB1(pSO), whose DNA-
binding properties are enhanced in the presence of MAD-3.
MAD-3 had no effect on the binding of the unrelated factor,
Spi, for its cognate site, and MAD-3 itself possessed no
detectable DNA-binding properties. This observation sug-
gests that MAD-3 is capable of interacting specifically with
Rel-related proteins without necessarily inhibiting their abil-
ity to bind DNA. This possibility is supported by two earlier
reports. The first of these (25) demonstrated that the ankyrin
repeat-containing protein, GABP-P, can enhance the DNA
binding of the Ets-related protein, GABP-a, and the second
(21) reported that antibodies raised against IKB could recog-
nize nuclear NF-KB. However, since overexpression of
MAD-3 inhibited KB-dependent transactivation in all cases
(Fig. 6), the stimulatory effect of MAD-3 on NFKB2(p49)
and NFKB1(p50) binding does not correlate with its func-
tional properties, and so the biological significance of this
unexpected effect is unclear. MAD-3 also prevented func-
tional activation of the HIV enhancer by NF-KB in Jurkat
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NFKB2(p49), NFKB1(p50), or RelA(p65) slightly stimulated
HIV-CAT through the KB site, and we have previously
postulated that this low-level stimulation may be due to
association with endogenous NF-KB subunits (38, 43). Co-
transfection of NFKB2(p49) or NFKB1(p50) with RelA
(p65), however, provided greater stimulation, particularly
with NFKB2(p49). Cotransfection of a MAD-3 expression
vector inhibited NFKB2(p49)/RelA(p65) or NFKB1(p50)/
RelA(p65) stimulation by 80 to 90% in all cases (Fig. 6A).
In summary, these data suggest that the protein encoded
by NFKB2 plays an important role in regulation of the HIV
enhancer. The role of this NF-KB subunit in the control of
other viral and cellular genes is not yet fully understood. The
recent identification of NFKB2 in association with translo-
cation in a B-cell lymphoma suggests that NFKB2 may also
contribute to the regulation of genes involved in cell cycle
regulation or oncogenesis. Despite the considerable struc-
tural similarity of NFKB1 and NFKB2, the data presented
here show that these gene products have distinct biochemi-
cal properties. These biochemical differences provide a
molecular basis to explain functional differences between
NFKB1 and NFKB2. These results also demonstrate that
despite their similarity, these DNA-binding subunits of
NF-KB differ significantly in the ability to stimulate tran-
scription. The interactions between alternative NF-KdB com-
plexes and other cellular transcription factors would thus
provide a mechanism to selectively regulate transcriptional
activation of the HIV enhancer, and they suggest that the
basis for the difference between the ability of NFKB2(p49)
and NFKB1(p50) to activate transcription is independent of
DNA-binding affinity.
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